mittee approved the study (certificate 308/2020), and an online survey was designed using a REDCap database hosted at the University of Pretoria 15,16 . The survey was administered to all nephrologists registered with the South African Renal Society between May and August 2020. All patient data was entered online by the treating nephrologist. Odds ratios were calculated using mortality as the outcome, with international comparative mortality data derived from Fominskiy et. al.Results: At the completion of the study, 142 responses were received. Of these, 52 (36.62%) were removed due to incomplete data or incomplete informed consent, resulting in 90 (63.38%) responses available for analysis. No significant increase in deaths was fond when comparing our data to international COVID-19 ICU mortality data (odds ratio [OR] 1.14, 95% confidence interval (CI) 0.64 -2.06, P = 0.6532), but a significant increase in mortality was seen when compared to international COVID-19 in-hospital mortality (OR 2.05, 95% CI 1.13 -3.72, P = 0.0176). Our data revealed that mortality was significantly increased in patients who were treated in the state sector (OR 2.15, 95% CI 1,00 -4,63, P = 0,0497) or were diagnosed with shock (OR 2.73, 95% CI 1.11 -6.71, P = 0.028). Similarly, mortality was significantly increased in patients who required ventilation (OR 2.24, 95% CI 1.10 -4.56, P = 0.026), inotropes (OR 2.78, 95% CI 1.26 -6.16, P = 0.0115) or continuous dialysis therapy (OR 3.11, 95% CI 1.33 -7.26, P = 0.0087). In contrast, mortality was significantly decreased in patients diagnosed with ischemic heart disease (OR 0.19, 95% CI 0.04 -0.95, P = 0.0431) and patients who received intermittent hemodialysis during their admission (OR 0.28, 95% CI 0.11 -0.72, P = 0.0081). Conclusions: 1) Our findings from a developing country are similar to developed countries.2) Significant predictors of mortality were continuous dialysis therapy, ventilation, inotropes, shock and treatment in the state sector.3) Significant predictors of survival were intermittent hemodialysis and ischemic heart disease.No conflict of interest